|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Karuna Therapeutics, Inc. (KRTX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
40,277,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Karuna Therapeutics is a clinical-stage biopharmaceutical company that focuses on transformative medicines for people living with psychiatric and neurological conditions. Co.'s proprietary product candidate, KarXT (xanomeline-trospium), an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT combines xanomeline, a muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS. Co. is developing KarXT for the treatment of psychosis in adults with schizophrenia as well as for the treatment of psychosis in Alzheimer's disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
120,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$14,736,159 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
10,000 |
40,000 |
152,929 |
353,217 |
| Total Sell Value |
$3,172,380 |
$10,837,466 |
$33,309,643 |
$74,839,995 |
| Total People Sold |
1 |
1 |
5 |
6 |
| Total Sell Transactions |
2 |
5 |
16 |
47 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Brannan Stephen K. |
Chief Medical Officer |
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$14,059,320 |
D/D |
(42,604) |
0 |
|
- |
|
| Torres Denice |
|
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$326,700 |
D/D |
(990) |
0 |
|
- |
|
| Brown Jason Parker |
Chief Financial Officer |
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$6,985,110 |
D/D |
(21,167) |
0 |
|
- |
|
| Jonas Jeffrey M |
|
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$326,700 |
D/D |
(990) |
0 |
|
- |
|
| Wheadon David E. |
|
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$326,700 |
D/D |
(990) |
0 |
|
- |
|
| Paul Steven M |
|
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$46,321,110 |
I/I |
(140,367) |
0 |
|
- |
|
| Paul Steven M |
|
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$3,496,680 |
D/D |
(10,596) |
0 |
|
- |
|
| Kane William P Jr |
Chief Commercial Officer |
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$4,563,240 |
D/D |
(13,828) |
0 |
|
- |
|
| Miller Andrew Craig |
President of R&D |
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$7,718,370 |
D/D |
(23,389) |
0 |
|
- |
|
| Healy James |
|
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$455,779,170 |
I/I |
(1,381,149) |
0 |
|
- |
|
| Healy James |
|
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$11,051,700 |
D/D |
(33,490) |
0 |
|
- |
|
| Olson Laurie J |
|
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$326,700 |
D/D |
(990) |
0 |
|
- |
|
| Pande Atul |
|
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$326,700 |
D/D |
(990) |
0 |
|
- |
|
| Coughlin Christopher J |
|
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$326,700 |
D/D |
(990) |
0 |
|
- |
|
| Meury William |
President and CEO |
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$9,695,070 |
D/D |
(29,379) |
0 |
|
- |
|
| Brannan Stephen K. |
Chief Medical Officer |
• – – |
2024-03-08 |
4 |
AS |
$318.33 |
$1,591,713 |
D/D |
(5,000) |
42,604 |
|
- |
|
| Brannan Stephen K. |
Chief Medical Officer |
• – – |
2024-03-08 |
4 |
OE |
$5.45 |
$636,596 |
D/D |
7,500 |
47,604 |
|
- |
|
| Paul Steven M |
|
– • – |
2024-03-04 |
4 |
GA |
$0.00 |
$0 |
I/I |
30,304 |
30,304 |
|
- |
|
| Paul Steven M |
|
– • – |
2024-03-04 |
4 |
GD |
$0.00 |
$0 |
I/I |
30,304 |
2,364 |
|
- |
|
| Paul Steven M |
|
– • – |
2024-03-01 |
4 |
GA |
$0.00 |
$0 |
I/I |
60,608 |
32,668 |
|
- |
|
| Paul Steven M |
|
– • – |
2024-03-01 |
4 |
GD |
$0.00 |
$0 |
I/I |
60,608 |
10,000 |
|
- |
|
| Paul Steven M |
|
– • – |
2024-02-29 |
4 |
A |
$315.18 |
$14,932,598 |
I/I |
47,378 |
70,608 |
|
- |
|
| Paul Steven M |
|
– • – |
2024-02-23 |
4 |
OE |
$7.27 |
$599,675 |
D/D |
31,518 |
42,114 |
|
- |
|
| Brown Jason Parker |
Chief Financial Officer |
• – – |
2024-02-13 |
4 |
D |
$318.00 |
$88,404 |
D/D |
(278) |
21,167 |
|
- |
|
| Miller Andrew Craig |
President of R&D |
• – – |
2024-02-09 |
4 |
D |
$317.14 |
$320,629 |
D/D |
(1,011) |
23,389 |
|
- |
|
347 Records found
|
|
Page 1 of 14 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
